ERBB2 and breast carcinoma: Similar results were observed in the repeat experiment.<h4>Conclusions</h4>In a mouse model of letrozole-resistant breast cancer with no ESR1 mutations, reduced levels of ERα, and overexpression of HER2, lasofoxifene alone or combined with palbociclib inhibited primary tumor growth more effectively than fulvestrant.